Skip to main content
. 2020 Sep 26;39(2):307–315. doi: 10.1007/s00345-020-03433-3

Fig. 2.

Fig. 2

Estimated relative risk of experiencing cardiovascular events in patients with prostate cancer treated with first-line degarelix (n = 101) vs leuprorelin (n = 3289), goserelin (n = 4366), triptorelin (n = 1325), and pooled GnRH agonists (n = 9081)